Faculty, Staff and Student Publications

Language

English

Publication Date

1-13-2026

Journal

npj Precision Oncology

DOI

10.1038/s41698-025-01261-5

PMID

41530472

PMCID

PMC12886979

PubMedCentral® Posted Date

1-13-2026

PubMedCentral® Full Text Version

Post-print

Abstract

We evaluated clinical outcomes and safety profiles in patients with non-small cell lung cancer (NSCLC) treated in early-phase trials. A retrospective review of 546 NSCLC cases treated from January 2016 to December 2024 at The University of Texas MD Anderson Cancer Center was performed using the MD Anderson CHIMERA database. Patients were categorized into seven groups based on treatment regimen. The overall objective response rate (ORR) was 19.9%, and the highest ORRs were in the targeted combination (30.8%) and targeted monotherapy (29.7%) groups. Gene alteration–matched therapy, serum albumin level, metastatic burden, treatment group, and liver metastasis were independently associated with progression-free survival. For overall survival, albumin level, metastatic burden, liver metastasis, and treatment regimen group showed independent significant associations. While overall safety profiles were tolerable, combination regimens were associated with increased proportions of grade ≥3 adverse events and dose modifications.

Keywords

Cancer, Oncology

Published Open-Access

yes

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.